Table of Contents
- Trial overview
- Who is being studied
- Trial design and treatment groups
- What the studies measure
- Why these trials matter
Trial overview
The main clinical trial in the source data is NCT04957719, titled “Selatogrel Outcome Study in Suspected Acute Myocardial Infarction.”[1] It is an interventional study, which means researchers give a study treatment and then measure the results.[1] The trial is listed as Authorised and is in Phase 3.[1]
The study is designed to assess the clinical efficacy of Selatogrel when it is self-administered at the start of symptoms suggestive of an acute myocardial infarction.[1] In simple terms, researchers want to know whether early use of the study treatment can help people who think they may be having a heart attack.[1]
Who is being studied
The target condition in this trial is acute myocardial infarction (AMI), which is the medical term for a heart attack.[1] The study brief says it is for subjects at risk of having a recurrent AMI, meaning another heart attack after a previous one.[1]
The trial focuses on people who can self-administer the treatment when symptoms suggest AMI.[1] This makes the study especially relevant for patients who may need to act quickly before reaching medical care.[1]
Trial design and treatment groups
The intervention list includes Selatogrel solution and a matching placebo solution.[1] A placebo is a look-alike treatment with no active study drug, used so researchers can compare results fairly.[1]
The Selatogrel dose listed in the trial data is 16 mg given by subcutaneous administration, which means under the skin.[1] The source data do not provide more detail on the full treatment schedule, but they do show that the study compares Selatogrel with matching placebo.[1]
The planned enrollment is 21,251 participants, which makes this a very large study.[1] Large trials can help researchers see both benefits and safety signals more clearly.[1]
What the studies measure
The main outcome is efficacy, or how well the treatment works.[1] The primary endpoint is a ranked outcome that includes death from any cause or non-fatal AMI after treatment self-administration.[1]
The ranking in the primary endpoint goes from the most severe event to less severe events: death, AMI with compromised electro-hemodynamics, STEMI, high-risk NSTEMI, NSTEMI with peak cardiac troponin greater than 10 times the upper limit of normal, and none of these events within 7 or 2 days after each treatment administration.[1] Electro-hemodynamics refers to the heart’s electrical and blood-flow stability, so “compromised” means the heart is not functioning normally in that way.[1]
The study also measures safety, with a focus on treatment-emergent bleeding events.[1] Specifically, it looks for type 3 or 5 bleeding events according to the Bleeding Academic Research Consortium (BARC) definition within 2 days after study treatment administration.[1] These are serious bleeding categories used in heart research.[1]
Why these trials matter
People with suspected heart attack often need fast action, so a trial that tests self-administration at symptom onset is aimed at a very early treatment window.[1] The study is trying to find out whether Selatogrel can improve important clinical outcomes in people already at risk for another AMI.[1]
Because the study includes both benefit measures and bleeding safety measures, it is designed to show not only whether the treatment may help, but also whether it may cause important harm.[1] This balance is especially important in heart attack research, where quick treatment and safety both matter.[1]
